



Supplementary Material: Clinical Evaluation of Acetaminophen-Galgeuntang Interaction Based on Population Approaches

Quyen Thi Tran, So Jung Park, Hyun-moon Back, Lien Thi Ngo, Duc Tuan Cao, Hung Van Nguyen, Sangkeun Jung, Jung-woo Chae, Yang Chun Park and Hwi-yeol Yun




Figure S1. Comparison of plasma concentration-time profiles of ephedrine after administration alone or co-administration with acetaminophen (AAP). Each point represents the mean and standard deviation. EPD, ephedrine.




Figure S2. Representative chromatogram of blank plasma (**A**), blank plasma spiked with internal standard (**B**), standard sample of AAP at dose of 2 μ g/mL (**C**), standard sample of EPD at dose of 0.5 μ g/mL (**D**), real sample of AAP at 3 h after administration combination of AAP and Galgeuntang (GGT) (**E**), real sample of EPD at 3 h after administration combination of AAP and GGT (**F**).

3 of 4

Table S1. Inclusion and exclusion of participants enrolling clinical trial.

Criteria	Contents				
	1. Men age from 20 to 45 years old				
T 1 ·	2. Body weight \geq 55 kg, and within \pm 20% IBW [1] (ideal body weight)				
Inclusion	3. Subject without any significant chronic disease				
criteria	4. No pathological conditions at time of screening				
	5. Adhere the protocol and sign in an informed consent form				
	1. Inflammatory fever				
	2. History of clinically significant hepatic, kidney, digestive system, pulmonary, blood, endocrine, urinary, neurology, musculoskeletal, immune, and				
	cardiovascular systems				
	3. History of gastrointestinal surgery or gastrointestinal disorders which may importantly affect absorption of drugs				
	4. Aspirin-induced asthma				
	5. Clinically significant allergies, including GGT components or AAP				
	6. Clinically significant vital sign:				
	-Systolic blood pressure > 140 or < 100 mmHg				
	-Diastolic blood pressure > 90 or < 60 mmHg				
	-Heart rate ≥ 100 beats/min				
	7. Clinical laboratory test values are outside the accepted normal range:				
Exclusion	-AST or ALT ≥ 2 times to the upper limit value				
criteria	-Total bilirubin > 2 times the upper limit value				
	8. Use of prescription medicines within 14 days or non-prescription medicines within 7 days before dosing				
	9. History of drug abuse				
	10. Renal impairment (Creatinine clearance < 50 mL/min)				
	11. Using drugs which related to inhibition or induction of our drugs within 1 month before dosing				
	12. Participated in other study within 3 months before dosing				
	13. Bleeding tendency in blood test				
	14. History of alcohol, smoking abuse:				
	-Alcohol > 210g/weeks				
	-Smoking ≥ 10 cigarettes/day				
	15. Donated blood within 2 months; received or had blood transfusion within 1 month before dosing				
	16. Subjected considered as unsuitable based on medical judgement by investigators				

	Concentration - (ng/mL)	Intra-day		Inter-day	
Compounds		Precision (%RSD)	Accuracy (%RE)	Precision (%RSD)	Accuracy (%RE)
	50	-1.06	6.92	3.94	4.49
Acetaminophen	2000	-0.853	5.58	1.17	5.11
	10,000	-0.0405	2.54	-5.21	3.85
	50	8.99	6.44	4.65	3.44
Ephedrine	500	-2.79	3.50	-6.06	6.25
-	2500	3.67	3.02	3.07	4.28

Table S2. Intra-day and inter-day of accuracies and precisions of AAP and EPD.

RSD: relative standard deviation, RE: relative error.

Table S3. NCA results of PK parameters of EPD.

	Mean		
Parameter	EPD (single)	EPD (+AAP)	
	<i>n</i> = 12	<i>n</i> = 11	<i>p</i> -value
AUC _{0-t} (ng h/mL)	969 ± 249	833 ± 217	<i>p</i> > 0.05
AUC _{inf} (ng h/mL)	1399 ± 496	1206 ± 313	<i>p</i> > 0.05
C _{max} (ng/mL)	142 ± 32.6	126 ± 27.3	<i>p</i> > 0.05
$T_{\max}(\mathbf{h})$	3.38 ± 1.11	3.55 ± 1.04	<i>p</i> > 0.05
<i>t</i> 1/2 (h)	5.82 ± 2.11	6.01 ± 3.22	<i>p</i> > 0.05
<i>CL/F</i> (mL/h)	25.1 ± 8.86	28.0 ± 8.14	<i>p</i> > 0.05
<i>V/F</i> (mL/h)	195 ± 60.7	225 ± 79.7	<i>p</i> > 0.05

<i>V/F</i> (mL/h)	195 ± 60.7	225 ± 79.7	<i>p</i> > 0.05			
AUC _{inf} , area under the plasma concentration-time curve from 0 to infinity; Cmax, maximum observed						
plasma concentration; T_{max} , ti	me to reach maximum ob	served concentration; t1/2, p	lasma half-life			
and sinted suith to main all allow		CI	alaanaa aa IZ			

plasma concentration; T_{max} , time to reach maximum observed concentration; $t_{1/2}$, plasma half-life associated with terminal slope of a semilogarithmic concentration-time curve; *CL*, clearance; *V*, volume of distribution; *F*, bioavailability; SD, standard deviation.

Reference:

1. Syahputra, M.F.; Felicia, V.; Rahmat, R.F.; Budiarto, R. Scheduling Diet for Diabetes Mellitus Patients using Genetic Algorithm. J. Phys. Conf. Ser. 2016, 755, doi:10.1088/1742-6596/755/1/011001.